Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31589356 | 0.86 | TNF (0.57) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL5358941 | 0.86 | TNF (0.57) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL30853086 | 0.81 | APAF1 (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL6326557 | 0.81 | APAF1 (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1536597 | 0.80 | TNF (0.48) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1205625 | 0.79 | TNF (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL25370499 | 0.77 | SMN1; SMN2 (0.49) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1536600 | 0.77 | TRPA1 (0.52) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL628689 | 0.77 | APAF1 (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL12463975 | 0.77 | TNF (0.46) | TNFPDE10APDE3BPDE3ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542516-B | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | SYNBLIA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | SYNBLIA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3704104-A1 | IRAK4 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111542516-A | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-6825181-B1 | ORALLY ADMINISTRATED TO EXHIBIT A STRONG ANTICOAGULANT EFFECT BY INHIBITING ACTIVATED BLOOD- COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | IRAK4, IRAK1, IRAK2 | TNF 95/4885PDE10A 2384/4885PDE3B 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.